Before it crumbles: Fulminant Hepatic Failure secondary to Hodgkin's Lymphoma by Paras Karmacharya et al.
CASE REPORT
Before it crumbles: Fulminant Hepatic Failure secondary
to Hodgkin’s Lymphoma
Paras Karmacharya, MD
1*, Naresh Bhandari, MD
2, Madan R. Aryal, MD
1,
Aashrayata A. Pandit, MBBS
3, Ranjan Pathak, MD
1,
Sailu Ghimire, MBBS
4, Pragya Shrestha, MBBS
5 and
Vijaya R. Bhatt, MBBS
6
1Department of Internal Medicine, Reading Health System, West Reading, PA, USA;
2Department of Internal
Medicine, Saint Agnes Hospital, Baltimore, MD, USA;
3Division of Cardiovascular Diseases, Mayo Clinic,
Scottsdale, AZ, USA;
4Department of Internal Medicine, College of Medical Sciences, Bharatpur, Nepal;
5Department of Internal Medicine, Nanjing Medical University, Nanjing, China;
6Department of Hematology
and Oncology, University of Nebraska Medical Center, Omaha, NE, USA
Fulminant hepatic failure (FHF) is a relatively rare manifestation of Hodgkin’s lymphoma. Clinical features,
laboratory findings, and imaging of the liver are usually inconclusive, and liver biopsy may be required for
confirmation. We present a case of an FHF in a woman 1 week after the diagnosis of Hodgkin’s lymphoma.
Chemotherapy could not be instituted due to hepatic encephalopathy and other complications. Autopsy
revealed diffuse infiltration of the liver parenchyma. This case illustrates the importance of early diagnosis
and institution of chemotherapy, which may reverse the liver failure.
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F
ulminant hepatic failure (FHF) is defined as the
development of coagulopathy and encephalopathy
within 8 weeks of the onset of liver dysfunction in
patients without pre-existing liver disease (1). The com-
mon causes of FHF include acute viral hepatitis, drugs,
toxins, ischemic hepatitis, and autoimmune hepatitis.
Occasionally, the worsening of pre-existing hepatic con-
dition may also mimic FHF (2). Hematologic malignan-
cies are infrequent (0.44%) but important causes (3, 4),
because liver transplant is contraindicated in this situa-
tion, hence early diagnosis and initiation of chemotherapy
are only hopes to alter the outcomes.
Case description
A 63-year-old woman presented with persistent high-
grade fever and night sweats for 1 week. Two weeks prior
to the presentation, the patient was diagnosed with
nodular sclerosing Hodgkin’s lymphoma (Fig. 1a and b)
stage IVon her lymph node and bone marrow biopsy. She
wasplannedtostartchemotherapybuthadtobeadmitted
for further workup. Medical history was significant for
daily alcohol consumption for the past 20 years.
Examination revealed a fully alert woman oriented to
time, place, and person. She had a temperature of 39.28F,
heart rate of 101/min, and mild icterus. There was no
palpable lymphadenopathy, hepatosplenomegaly, or any
stigmata of chronic liver disease. Laboratory tests re-
vealed white cell count (WBC) of 3.810
9/L, hemoglo-
bin of 8.3 g/dl, platelet count of 6010
9/L, total bilirubin
of 1.7 mg/dl, direct bilirubin level of 0.9 mg/dl, alanine
transaminase (ALT) of 35 IU/L, aspartate transaminase
(AST) of 28 IU/L, alkaline phosphatase (ALP) of 231 IU/L,
prothrombin time (PT) of 16.9 sec (normal 10.211.7 sec),
international normalized ratio (INR) of 1.5, partial
thromboplastin time (PTT) of 36 sec (normal 2533 sec),
albumin of 1.3 g/dl, and lactate dehydrogenase (LDH) of
156 IU/L (normal 94202 IU/L). Blood cultures, urine
culture, and sputum culture were sent, which subse-
quently turned out to be negative. Computed tomography
(CT) scan of the chest, abdomen, and pelvis did not
reveal any source of infection. She was empirically started
on intravenous vancomycin and piperacillin-tazobactam.
Serological tests for Cytomegalovirus, EpsteinBarr virus,
and Cryptococcus were also negative.
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grade III encephalopathy and worsening pancytopenia.
CT scan and magnetic resonance imaging of the brain
were normal. Lumbar puncture was avoided due to severe
thrombocytopenia (1110
9/L). Liver function tests re-
vealed a direct bilirubin of 9.6 mg/dl, total bilirubin of
15.2 mg/dl, INRof 1.9, ASTof 48 IU/L, ALTof 48 IU/L,
and ALP of 170 IU/L (Table 1). Ultrasonogram and
Doppler imaging of the abdomen revealed mild spleno-
megaly with no ascites, normal hepatic size, echo texture,
and normal hepatic veins. Serological studies for hepatitis
A, B, and C viruses and human immunodeficiency virus
were negative. Blood alcohol, acetaminophen, salicylate
levels, a-feto protein level, and urine toxicology were
all negative. Antinuclear antibody was positive (1:80,
speckled), but anti-mitochondrial and anti-smooth mus-
cle antibodies were negative.
A possibility of advanced Hodgkin’s disease (HD)
infiltrating the liver was entertained. A liver biopsy was
withheld due to significant thrombocytopenia, coagulo-
pathy (Fig. 2), and encephalopathy. She was determined
to be a poor candidate for emergent liver transplantation
because of the history of HD and alcohol abuse. She was
also determined to be a poor candidate for chemotherapy
because of hepatic encephalopathy. After a lengthy discus-
sion with family members, given the poor prognosis from
FHF and advanced lymphoma, the patient was transi-
tioned to comfort cares and passed away shortly there-
after. An autopsy revealed lymphocyte-depleted HD (in
contrast to earlier bone marrow biopsy showing nodular
sclerosing type) extensively involving liver, spleen, cervical,
supraclavicular, mediastinal, and retroperitoneal lymph
nodes. The pathologic examination of the liver showed
small nodules of cancer as well as infiltrative neoplastic
pattern characterized by areas of necrosis, characteristic
ReedSternberg cells, and areas of hypocellularity in an
eosinophilic fibrillar background (Fig. 3a and b).
Discussion
The patient reported here developed FHF soon after the
diagnosis of HD. The patient did not have any history of
liver disease and autopsy did not reveal any evidence of
chronic liver disease, thus confirming that hepatic infil-
tration by HD was the cause of FHF. Hepatic involve-
ment is seen in approximately one-fourth of the cases of
lymphoma, which ranges from a mild hepatic dysfunction
to FHF (5). Few mechanisms have been implicated for
hepatic dysfunction in lymphoma, including the infiltra-
tion of the liver parenchyma, biliary tree, or hepatic
vasculature. Also, vanishing bile duct syndrome resulting
from cytokine release with interlobular bile duct destruc-
tion and portal fibrosis, and rarely a paraneoplastic syn-
drome with no liver infiltration have been described (2, 5, 6).
Fig. 1. (a) High power view of Level 7 lymph node from the neck showing atypical cells, some of which are multinucleated and
consistent with ReedSternberg (RS) cells although not typical. (b) Immunohistochemical stain showing RS cells positive for
CD30.
Table 1. Laboratory parameters showing deterioration of
coagulation parameters
Labs Day 1 Day 8 Day 15
WBC (10
3/mm
3) 4.8 2.3 4.8
Hb (g/dl) 6.5 7.2 7.4
Platelets (10
3/mm
3) 145 54 18
AST (IU/L) 42 28 42
ALT (IU/L) 50 35 47
ALP (IU/L) 290 231 131
Total bilirubin (mg/dl) 1.4 1.7 10.6
Direct bilirubin (mg/dl) 0.5 0.9 6.9
PT (sec) 12.7 16.9 17.8
INR 1.2 1.5 1.6
PTT (sec) 31 36 NA
Albumin (g/dl) 1.7 1.3 1
LDH (IU/L) 410 156 NA
WBCwhite cell count; Hbhemoglobin; ALTalanine transami-
nase; ASTaspartate transaminase; ALPalkaline phosphatase;
PTprothrombin time; INRinternational normalized ratio; PTT
partial thromboplastin time; LDHlactate dehydrogenase.
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as in the reported case, the obstruction of small vessels by
neoplastic cells leading to liver anoxia has been impli-
cated as the cause of hepatic failure.
Hepatic involvement on staging laparotomy has been
reported more frequently in cases of non-Hodgkin’s
lymphoma (1622%) and leukemia as compared to HD
(58%); however, FHF is a rare complication (0.44%)
(3, 4). Although all types of HD have been implicated,
lymphocyte-depleted HD seems to be the most common
type associated with hepatic involvement (7). Hepatic
involvement mayoccur at various stages of HD. Although
it is usually seen during advanced stages, FHF can be the
presenting feature of HD on rare occasions (2, 6, 8, 9).
The clinical picture is usually indistinguishable from other
causes of FHF, and diagnosis may only be made at
autopsy. Therefore, a core biopsy of liver is required for
confirmation (10). Less than 10% of percutaneous liver
biopsies show liver infiltration by lymphoma because
the ReedSternberg cells can have a patchy distribution.
Laparoscopic-guided biopsies and immunohistochemis-
try may improve the diagnostic yield (4, 9). The presence
of mononuclear variants of ReedSternberg cells is enough
for a diagnosis of hepatic involvement in an established
case of HD. However, classical multi-nucleated Reed
Sternberg cells is required if liver is the only organ
involved (8).
Early diagnosis is important as early institution of
chemotherapy may reverse the hepatic dysfunction. Delay
in diagnosis is common because of normal liver imaging,
as in the reported case, its rarity, and lack of awareness.
With the development of FHF, the prognosis is dismal
despite treatment. Coagulopathy and thrombocytopenia
increases the risk of liver biopsy whereas hepatic failure
increases the complications from chemotherapy. None-
theless, the liver biopsy and chemotherapy should still be
considered and discussed with the patient and the family.
One of the studies showed that in select cases, there may
be no increase in morbidity or mortality due to the liver
biopsy with the utilization of fresh frozen plasma and
platelet transfusion as clinically indicated (10).
Although liver transplant remains the mainstay of
treatment for FHF from other causes, it is contraindi-
cated in hematological malignancy (2). In patients with
Fig. 2. Graph showing deterioration of coagulation parameters.
Fig. 3. (a) Liver biopsy showing diffuse inﬁltration of liver by lymphoma cells with disruption of hepatic architecture and
necrosis. (b) Liver biopsy showing hepatocellular necrosis and malignant inﬁltrate of lymphoma cells.
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may still be the treatment of choice. At least partial res-
ponse to the treatment has been observed in many cases
when used early on (2, 5). The most appropriate chemo-
therapy regimen for HD with liver failure remains uncer-
tain as most of these drugs are associated with liver
dysfunction. The use of dexamethasone, cytarabine, and
cisplatin (DHAP) may be safe and effective without dose
modification in patients with severe liver dysfunction (6).
Other regimens that may be considered include etoposide,
methylprednisone, cytarabine, and cisplatin- (ESHAP)
and ifosfamide-based regimens (9). Radiotherapy may be
beneficial in early stages to extra-hepatic sites and may
improve hepatic dysfunction, especially in cases of vanish-
ing bile duct syndrome (6). The prognosis is usually poor
with a mean survival of 6 days (range 151 days) after
admission in a case series (n18, of which three cases
were from HD). All HD cases died because of sepsis and
multiorgan failure (10). In most reported cases, patients
either succumb to FHF, multiorgan failure, or sepsis as a
complication of chemotherapy-induced immunosuppres-
sion (6). There are a few reports of HD with FHF where
liver transplantation was lifesaving, however, HD recurred
in the transplanted liver (6, 11). Early diagnosis and ini-
tiation of chemotherapy before the development of FHF
can improve outcomes in select cases (12).
HD infiltrating the liver frequently represents lympho-
cyte-depleted extranodal HD, which is expected to have
worse prognosis. Given their very aggressive course, whether
HD with FHF represents a unique subset of disease with
different pathobiology remains speculative. In the re-
ported case, a nodular sclerosis HD was diagnosed in
a bone marrow biopsy, whereas evaluation at autopsy
demonstrated lymphocyte-depleted HD. Apart from the
possibility that a bone marrow biopsy is imperfect for the
diagnosis of lymphoma subtypes, we do not have a good
explanation for this phenomenon.
Conclusion
Hepatic dysfunction in HD patient may reflect involve-
ment of liver by lymphoma. Given the riskof FHF, which
may preclude subsequent liver biopsy and therapy, an
early liver biopsy should be considered in such patients.
In HD patients with FHF, who cannot undergo a liver
biopsy, whether an empiric use of chemotherapy alters
the outcome is unclear (given the rarity of this condition).
If a decision is made to treat such patients, patients may
be treated with dose-adjusted chemotherapy. The optimal
chemotherapy regimen remains unclear but drugs meta-
bolized by liver such as adriamycin and vinblastine needs
dose reduction based on the degree of hyperbilirubinemia.
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